Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy

Prasanna Duraisamy; Vinitha Panicker; Wesley Jose

doi:10.5826/dpc.1303a127

Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy

Authors

Prasanna Duraisamy Department of Dermatology, Amrita Institute of Medical Sciences, Kochi, India
Vinitha Panicker Department of Dermatology, Amrita Institute of Medical Sciences, Kochi, India
Wesley Jose Department of Medical Oncology and Hematology, Amrita Institute of Medical Sciences, Kochi, India

Keywords:

immune checkpoint inhibitors, cutaneous immune related adverse events, immunotherapy, reactions

Abstract

Introduction: Cutaneous immune-related adverse-events (cIRAEs), commonly seen in cancer patients receiving immune checkpoint inhibitors (ICI) are reported to be associated with better patient survival; however, they have seldom been studied in Indian population. Recent reports suggest racial differences in IRAEs and also in survival outcomes.

Objective: To study the various cIRAEs in Indian patients on ICI therapy and to analyze the association between cIRAEs and patient survival outcomes.

Methods: We conducted a retrospective cohort study of 86 cancer patients receiving immunotherapies in a tertiary care hospital in India and studied incidence, nature and grades of cutaneous immune-related adverse events and the association of cIRAEs with the patient survival outcomes.

Results: Eighty-six patients were included, of whom 16 patients (18.6%) developed cIRAEs, with pruritus (12.8%) and maculopapular eruption (8.1%) being the most common. Kaplan–Meier plot with log-rank test showed that patients developing any type of cIRAE had longer progression-free survival than those without (p=0.023) and a better objective-response-rate (50% vs 18.5%, p=0.008).

Conclusion: Most common cIRAEs in our study were pruritus and maculopapular rash. The incidence of cIRAEs was lower in our Indian cohort compared to that reported in Caucasian cohorts. Development of cutaneous immune-related adverse event in cancer patients on ICI was associated with a longer progression-free-survival and a better objective-response-rate. Thus, cIRAEs may serve as a surrogate marker for better patient outcomes.

References

Lee L, Gupta M, Sahasranaman S. Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. J Clin Pharmacol. 2016;56(2):157–169. DOI:10.1002/jcph.591. PMID: 26183909.

Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. DOI:10.1038/s41572-020-0160-6. PMID: 32382051. PMCID: PMC9728094.

Rogado J, Sánchez-Torres JM, Romero-Laorden N, et al. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer. 2019;109:21-27. DOI:10.1016/j.ejca.2018.10.014. PMID: 30682533.

Thompson LL, Chang MS, Polyakov NJ, et al. Prognostic significance of cutaneous immune-related adverse events in patients with melanoma and other cancers on immune checkpoint inhibitors. J Am Acad Dermatol. 2022;86(4):886-889. DOI:10.1016/j.jaad.2021.03.024. PMID: 33722547.

Haratani K, Hayashi H, Chiba Y, et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. JAMA Oncol. 2018;4(3):374-378. DOI:10.1001/jamaoncol.2017.2925. PMID: 28975219. PMCID: PMC6583041.

Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol. 2015;151(11):1206-1212. DOI:10.1001/jamadermatol.2015.1916. PMID: 26222619. PMCID: PMC5061067.

Lee J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer? J Thorac Dis. 2020;12(7):3796–803. DOI:10.21037/jtd.2019.08.29. PMID: 32802459. PMCID: PMC7399433.

Florez MA, Kemnade JO, Chen N, et al. Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access. Cancer Res Commun. 2022;2022(8):806–813. DOI: 10.1158/2767-9764.CRC-21-0143. PMID: 35966167. PMCID: PMC9367161.

Resnick K, Zang P, Travis Larsen T, et al. Impact of ethnicity and immune-related adverse events (IRAE) on outcomes for non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors. J Clin Oncol. 2022;40:16:suppl, e21115-e21115. DOI: 10.1200/JCO.2022.40.16_suppl.e21115.

Peravali M, Gomes-Lima C, Tefera E, et al. Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses. World J Clin Oncol. 2021;12(2):103-114. DOI:10.5306/wjco.v12.i2.103. PMID: 33680877. PMCID: PMC7918525.

Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073-4126. DOI:10.1200/JCO.21.01440. PMID: 34724392.

Wongvibulsin S, Pahalyants V, Kalinich M, et al. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis. J Am Acad Dermatol. 2022;86(3):563-572. DOI:10.1016/j.jaad.2021.03.094. PMID: 33819538.

Cho YT, Lin YT, Yang CW, Chu CY. Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit. Sci Rep. 2022;12(1):7021. DOI: 10.1038/s41598-022-11128-5. PMID: 35487955. PMCID: PMC9055047.

Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor—related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255–1268. DOI:10.1016/j.jaad.2020.03.132. PMID: 32454097. PMCID: PMC7572894.

Wang E, Kraehenbuehl L, Ketosugbo K, Kern JA, Lacouture ME, Leung DYM. Immune-related cutaneous adverse events due to checkpoint inhibitors. Ann Allergy Asthma Immunol. 2021;126(6):613–622. DOI:10.1016/j.anai.2021.02.009. PMID: 33609771. PMCID: PMC8165024.

Larsabal M, Marti A, Jacquemin C, et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol. 2017;76(5):863-870. DOI:10.1016/j.jaad.2016.10.044. PMID: 28094061.

Malviya N, Tattersall IW, Leventhal J, Alloo A. Cutaneous immune-related adverse events to checkpoint inhibitors. Clin Dermatol. 2020;38(6):660–678. DOI:10.1016/j.clindermatol.2020.06.011. PMID: 33341200.

Thompson LL, Krasnow NA, Chang MS, et al. Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer. JAMA Dermatol. 2021;157(5):577–582. DOI:10.1001/jamadermatol.2021.0326. PMID: 33760001. PMCID: PMC7992016.

Fujii T, Colen RR, Bilen MA, et al. Incidence of immune-related adverse events and its association with treatment outcomes: The MD Anderson Cancer Center experience. Invest New Drugs. 2018;36(4):638–646. DOI: 10.1007/s10637-017-0534-0. PMID: 29159766. PMCID: PMC5962379.

Rose LM, DeBerg HA, Vishnu P, et al. Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors. Front Oncol. 2021;10:570752. DOI: 10.3389/fonc.2020.570752. PMID: 33520695. PMCID: PMC7844139.

Phillips GS, Wu J, Hellmann MD, et al. Treatment Outcomes of Immune-Related Cutaneous Adverse Events. J Clin Oncol. 2019;37(30):2746–2758. DOI:10.1200/JCO.18.02141. PMID: 31216228. PMCID: PMC7001790.

Gault A, Anderson AE, Plummer R, et al. Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors. Br J Dermatol. 2021;185(2):263–271. DOI:10.1111/bjd.19750. PMID: 33393076.